RT @ericdeinmd: L15 #ACR22 SURPASS: SEC vs bsADA (SDZ-ADL) on radiographic progression of AS P3b: SEC 150 mg v SEC 300 v
Tweet Content
L15 #ACR22 SURPASS: SEC vs bsADA (SDZ-ADL) on radiographic progression of AS
P3b: SEC 150 mg v SEC 300 v SDZ-ADL
Wk 104: no radiographic progression in 66%, 67%, 66% - no statistical significance
Hard to assess as overall, low rate of progression
@RheumNow
Show on Archive Page
On
Display in Search Results
On
PDQ
Off